Search Results Search Sort by RelevanceMost Recent Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Viewpoint Jun 2008 Medical Care for the Elderly: Should Limits Be Set? Commentary 1 Daniel Callahan, PhD Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care? Virtual Mentor. 2008;10(6):404-407. doi: 10.1001/virtualmentor.2008.10.6.oped1-0806. Case and Commentary Jun 2018 Is It Ethical to Treat Pain Differently in Children and Adults with Burns? Sharmila Dissanaike, MD Pain management of adult and pediatric burn patients should be individualized and include nonpharmacological treatment. AMA J Ethics. 2018;20(6):531-536. doi: 10.1001/journalofethics.2018.20.6.cscm1-1806. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Medicine and Society Aug 2019 Does Incorporating Cost-Effectiveness Analysis Into Prescribing Decisions Promote Drug Access Equity? Michael J. DiStefano, MBE and Jonathan S. Levin, MPH Advances in CEA methodology might integrate equity at the cost of transparency. AMA J Ethics. 2019;21(8):E679-685. doi: 10.1001/amajethics.2019.679. Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Viewpoint Jun 2008 Medical Care for the Elderly: Should Limits Be Set? Commentary 1 Daniel Callahan, PhD Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care? Virtual Mentor. 2008;10(6):404-407. doi: 10.1001/virtualmentor.2008.10.6.oped1-0806.
Case and Commentary Jun 2018 Is It Ethical to Treat Pain Differently in Children and Adults with Burns? Sharmila Dissanaike, MD Pain management of adult and pediatric burn patients should be individualized and include nonpharmacological treatment. AMA J Ethics. 2018;20(6):531-536. doi: 10.1001/journalofethics.2018.20.6.cscm1-1806.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
Medicine and Society Aug 2019 Does Incorporating Cost-Effectiveness Analysis Into Prescribing Decisions Promote Drug Access Equity? Michael J. DiStefano, MBE and Jonathan S. Levin, MPH Advances in CEA methodology might integrate equity at the cost of transparency. AMA J Ethics. 2019;21(8):E679-685. doi: 10.1001/amajethics.2019.679.